Picture of Santhera Pharmaceuticals Holding AG logo

SANN Santhera Pharmaceuticals Holding AG Income Statement

0.000.00%
ch flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for Santhera Pharmaceuticals Holding AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSPRESS
Standards:
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue75.415-1.597.47103
Cost of Revenue
Gross Profit69.94.58-5.363.88100
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses85.868.155.459.434.6
Operating Profit-10.4-53.1-56.9-5268.8
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-18.4-67.5-54.8-70.654.8
Provision for Income Taxes
Net Income After Taxes-19-67.7-55.6-71.154.8
Net Income Before Extraordinary Items
Net Income-19-67.7-55.6-71.154.8
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-19-67.7-55.6-71.154.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-17.3-50.8-16.3-113.28
Dividends per Share